View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …

View Post

Polyphor’s balixafortide activity in advanced Her2-negative HR+ metastatic breast cancer fortifies Phase III chances

In Clinical Studies News by Barbara Jacoby

Source: GlobalData Healthcare From: pharmaceutical-technology.com by Manasi Vaidya in New York Polyphor’s positive balixafortide activity with Eisai’s Halaven (eribulin), along with the mechanistic potential, buttress Phase III prospects in Her2-negative HR+ metastatic breast cancer, said experts. Prior Phase I efficacy with balixafortide in combination with the chemotherapy Halaven in Her2-negative HR+ metastatic breast cancer patients is significant given the advanced …

View Post

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

In In The News by Barbara Jacoby

From: businesswire.com Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. …

View Post

FDA OKs Pembrolizumab in Advanced TNBC

In Clinical Studies News by Barbara Jacoby

By: Ian Ingram From: medpagetoday.com Checkpoint inhibitor nabs accelerated approval for PD-L1 expressors The FDA on Friday granted accelerated approval to pembrolizumab (Keytruda) for treating triple-negative breast cancer (TNBC) patients with metastatic or locally recurrent unresectable disease. TNBC becomes the astonishing 18th cancer indication for pembrolizumab, which was first approved in 2014 for advanced or unresectable melanoma. Pembrolizumab, a PD-1-directed …

View Post

New Research Study Supports Clinical Utility of Circulating Tumor Cell Count for Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

First randomized clinical trial demonstrating that CTC count may help personalize treatment choices Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer. Published in …

View Post

New study sheds light on the best drug choices for some patients with advanced breast cancer

In Clinical Studies News by Barbara Jacoby

By: Institute of Cancer Research From: medicalxpress.com Patients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study. In a combined analysis of two major Phase III clinical trials, called SoFEA and EFECT, researchers were able to show that …

View Post

Trial finds benefit of immunotherapy-chemotherapy combination in early-stage triple-negative breast cancer

In Clinical Studies News by Barbara Jacoby

By: Dana Farber Cancer Institute From: medicalxpress.com Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham and Women’s Cancer Center suggests. The results of the trial, dubbed the IMpassion031 study, will be presented at the 2020 Congress of …

View Post

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Business Wire cliFrom: galvnews.com Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer. The manuscript appears in the October 5, 2020 online issue accessible at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext. ExteNET was a multicenter, randomized, double-blind, …

View Post

Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Krystle Vermes Source: BioSpace From: pharmalive.com Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints. F-627, also known as efbemalenograstim alpha, works by increasing the production of white blood cells. A low concentration of these cells is a common side effect …

View Post

Junjie Li, MD, on Capecitabine in Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com Clinical trial focused exclusively on TNBC patients Current breast cancer treatment guidelines suggest that capecitabine (Xeloda) should be considered for adjuvant treatment after standard neoadjuvant therapy with taxane- and anthracycline-based chemotherapy. However, although randomized trials have evaluated capecitabine as adjuvant treatment in breast cancer overall as well as in elderly patients, none have focused solely …